Diabetes Research and Clinical Practice
Volume 87, Issue 1 , Pages 108-116 , January 2010

Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: A retrospective database analysis

  • Lauren J. Lee

      Affiliations

    • Eli Lilly and Company, Global Health Outcomes, Indianapolis, IN, United States
    • ,
  • Andrew P. Yu

      Affiliations

    • Analysis Group, Inc., Boston, MA, United States
    • ,
  • Scott J. Johnson

      Affiliations

    • Analysis Group, Inc., Boston, MA, United States
    • Corresponding Author InformationCorresponding author at: Analysis Group, Inc., New York, NY 10020, United States. Tel.: +1 212 492 8130; fax: +1 212 492 8188.
    • ,
  • Howard G. Birnbaum

      Affiliations

    • Analysis Group, Inc., Boston, MA, United States
    • ,
  • Pavel Atanasov

      Affiliations

    • Analysis Group, Inc., Boston, MA, United States
    • ,
  • Don P. Buesching

      Affiliations

    • Eli Lilly and Company, Global Health Outcomes, Indianapolis, IN, United States
    • ,
  • Jeffrey A. Jackson

      Affiliations

    • Lilly USA, LLC, US Medical Division, Indianapolis, IN, United States
    • ,
  • Jaime A. Davidson

      Affiliations

    • Department of Medicine, University of Texas, Southwestern Medical School, Dallas, TX, United States

Received 12 November 2008 ,Revised 27 August 2009 ,Accepted 28 September 2009.

References 

  1. Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM, Engelgau MM, et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population. Diabetes Care. 2006;29:1263–1268
  2. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National diabetes statistics, Available from http://diabetes.niddk.nih.gov, 2007 (last accessed 9/1/2008).
  3. American Diabetes Association . Economic costs of diabetes in the U.S. in 2007. Diabetes Care. 2008;31:1–20
  4. The Diabetes Control Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993;329:977–986
  5. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res. Clin. Pract. 1995;28:103–117
  6. UK Prospective Diabetes Study (UKPDS) Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  7. UK Prospective Diabetes Study (UKPDS) Group . Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–865
  8. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 2008;359:1–13
  9. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005–2012
  10. Bazzano LA, Lee LJ, Shi L, Reynolds K, Jackson JA, Fonseca V. Safety and efficacy of glargine versus NPH insulin for the treatment of type 2 diabetes: a meta-analysis of randomized controlled trials. Diabet. Med. 2008;25(8):924–932
  11. Bullano MF, Al-Zakwani IS, Fisher MD, Menditto L, Willey VJ. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products. Curr. Med. Res. Opin. 2005;21(2):291–298
  12. Miller DR, Gardner JA, Hendricks AM, Zhang Q, Fincke BG. Health care resource utilization and expenditures associated with the use of insulin glargine. Clin. Ther. 2007;29(3):478–487
  13. Zhang Q, Menditto L. Incremental cost savings 6 months following initiation of insulin glargine in a Medicaid fee-for-service sample. Am. J. Ther. 2005;12:337–343
  14. Leahy JL, Dain MP, Rhoads G, Kennedy L. 2-year glycemic control following initiation of insulin glargine versus NPH insulin in individuals with type 2 diabetes. Value Health. 2007;10:257;(PDB214)
  15. Leahy JL, Rhoads G, Wei W. Lower rate of hospitalization in subsequent year of insulin glargine vs NPH initiation in individuals with type 2 diabetes. Value Health. 2007;10:258;(PDB215)
  16. Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes. 2000;49(6):999–1005
  17. Jovanovic L, Pettitt DJ. Treatment with insulin and its analogs in pregnancies complicated by diabetes. Diabetes Care. 2007;30(2):S220–S224
  18. Ramsey S, Summers KH, Leong SA, Birnbaum HG, Kemner JE, Greenberg P. Productivity and medical costs of diabetes in a large employer population. Diabetes Care. 2002;25(1):23–29
  19. Lee LJ, Yu AP, Cahill KE, Oglesby AK, Tang J, Qiu Y, et al. Direct and indirect costs among employees with diabetic retinopathy in the United States. Curr. Med. Res. Opin. 2008;24(5):1549–1559
  20. Birnbaum H, Leong S, Kabra A. Lifetime medical costs for women: cardiovascular disease, diabetes, and stress urinary incontinence. Womens Health Issues. 2003;13(6):204–213
  21. Crémieux PY, Buchwald H, Shikora SA, Ghosh A, Yang HE, Buessing M. A study on the economic impact of bariatric surgery. Am. J. Manag. Care. 2008;14(9):589–596
  22. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41–55
  23. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. JCE. 1992;45(6):613–619
  24. Rosenbaum PR. Observational Studies. 2nd ed.. New York: Springer; 2002;
  25. Riddle MC, Rosenstock J, Gerich J, The Insulin Glargine 4002 Study Investigators . The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080–3086
  26. Mullins P, Sharplin P, Yki-Jarvinen H, Riddle MC, Haring H-U. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven phase III and IV studies of insulin glargine compared with neutral protamine hagedorn insulin type 1 and type 2 diabetes mellitus. Clin. Ther. 2007;29:1607–1619
  27. Metzger BE, Buchanan TA, Coustan DR, de Leiva A, Dunger DB, Hadden DR, et al. Summary and recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus. Diabetes Care. 2007;30(2):S251–S260
  28. Riddle MC. Timely initiation of basal insulin. Am. J. Med. 2004;116(3A):3S–9S
  29. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2006;29:1963–1972
  30. Henderson JN, Allen KV, Deary IJ, Frier BM. Hypoglycaemia in insulin-treated type 2 diabetes: frequency, symptoms and impaired awareness. Diabet. Med. 2003;20:1016–1021
  31. Miller CD, Phillips LS, Ziemer DC, Gallina DL, Cook CB, El-Kebbi IM. Hypoglycemia in patients with type 2 diabetes mellitus. Arch. Intern. Med. 2001;161:1653–1659
  32. UK Hypoglycemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50:1140–1147

PII: S0168-8227(09)00415-X

doi: 10.1016/j.diabres.2009.09.023

Diabetes Research and Clinical Practice
Volume 87, Issue 1 , Pages 108-116 , January 2010

Article Tools

* Image Usage & Resolution